Use of cookies

Lund University uses cookies to ensure that the website functions properly and to improve your experience.

Read more in our cookie policy

Search results

Filter

Reset filter

Filetype

Your search for "*" yielded 121533 hits

Accessibility report

We are continuesly working on the accessibility of this webpage. This document describes how well tcr.lu.se complies with the accessibility regulations, any known accessibility issues, and how you can report problems so that we can fix them. If you experience any issues visiting our site we ask that you please contact us and let us know: johanna.verngren@med.lu.se How accessible is tcr.lu.se?This

https://www.tcr.lu.se/accessibility-report - 2025-04-25

Breast/Lung cancer

PI Johan Staaf Breast Cancer researchBreast cancer is the most common malignancy in women and a heterogeneous disease at the molecular level. This heterogeneity translates into differences in clinical manifestation, patient therapies, and ultimately patient outcome. TNBC is a subgroup of breast cancer, representing ~10% of all cases (9% in Sweden 2015). To date, this patient subgroup has often had

https://www.tcr.lu.se/research-groups/breastlung-cancer - 2025-04-25

Translational Cancer Research

Our task is to understand the basic mechanisms behind tumor development. This understanding provides a basis for matching the right drug with the right patient and thereby offer better conditions for individualized treatment of cancer patients. The Division of Translational Cancer Research (TCR) was founded 2013 in conjunction with the formation of Lund University Cancer Center (LUCC) at Medicon V

https://www.tcr.lu.se/translational-cancer-research - 2025-04-25

Medical Molecular Biology

PI Yvonne Ceder Our researchOur research aims to deduce the role of microRNAs in prostate cancer initiation and progression. The focus of our research is on the miRNA regulation of the transient processes leading to tumor progression and metastases as the reversibility of this type of regulation present a possible interference option. To capture the dynamic events occurring as the tumour cells tra

https://www.tcr.lu.se/research-groups/medical-molecular-biology - 2025-04-25

Tumor Cell Biology

PI Christer Larsson Our researchOur aims are to identify and understand mechanisms regulating breast cancer cell death and how inflammatory signaling can be induced and influence breast cancer progression. We specifically study Smac mimetics, small molecules mimicking the effect of the pro-apoptotic protein Smac. We investigate determinants of Smac-responsiveness and ways to circumvent resistance

https://www.tcr.lu.se/research-groups/tumor-cell-biology - 2025-04-25

Immuno-Oncology Group

PI Charlotte Rolny ResearchOur research primarily focuses on tumor immunology, with a particular emphasis on understanding the behavior of Tumor-Associated Macrophages (TAMs) and is dedicated to finding novel targets that reprogram immunosuppressive and pro-metastatic Tumor-Associated Macrophages into an anti-tumor phenotype. Our lab employs state-of-the-art molecular biology techniques, mouse mod

https://www.tcr.lu.se/research-groups/immuno-oncology-group - 2025-04-25

Selected publications

VEGF-C-expressing TAMs rewire the metastatic fate of breast cancer cells.Banerjee K, Kerzel T, Bekkhus T, Ferreira de Souza S, Wallmann T, Wallerius M, Landwehr LS, Agardy DA, Schauer N, Malmerfeldt A, Bergh J, Bartish M, Hartman J, Östman A, Squadrito ML and Rolny C. Cell Reports. 2023 Dec 1;42(12):113507. doi: 10.1016/j.celrep.2023.113507  MNK2 governs the macrophage antiinflammatory phenotype.B

https://www.tcr.lu.se/research-groups/charlotte-rolny/selected-publications - 2025-04-25

Molecular Pediatric Oncology

PI Daniel Bexell Our researchOur research is about childhood cancer neuroblastoma. We work to understand the mechanisms leading to metastasis and treatment resistant relapse, and to test new treatment against aggressive neuroblastoma. Our projects encompass studies on basic tumor biology as well as preclinical and translational studies with the aim to find novel treatments. We perform molecular an

https://www.tcr.lu.se/research-groups/molecular-pediatric-oncology - 2025-04-25

Seminar Ida Skarping

16 May 2025 13:15 to 14:00 | Seminar TCR-Oncology Friday Seminar SeriesHybrid: Bioforum and ZoomContinue discussions afterwards with fika in the lunch room area. About the eventLocation:BioforumContact:gottfrid [dot] sjodahl [at] med [dot] lu [dot] se Save the event to your calendar

https://www.tcr.lu.se/calendar/seminar-ida-skarping - 2025-04-25

Seminar Maria Kotevska

13 June 2025 13:15 to 14:00 | Seminar TCR-Oncology Friday Seminar SeriesHybrid: Bioforum and ZoomContinue discussions afterwards with fika in the lunch room area. About the eventLocation:BioforumContact:gottfrid [dot] sjodahl [at] med [dot] lu [dot] se Save the event to your calendar

https://www.tcr.lu.se/calendar/seminar-maria-kotevska - 2025-04-25

Molecular Tumor Pathology

PI Ramin Massoumi Our researchThe overall goal of our research is to characterize the function of certain genes in development biology and immunology. In addition, we try to identify driver genes that are defined as being linked to human diseases such as cancer and fibrosis. Dissecting the signalling pathway with the focus on the post-translational modifications, will allow us to identify potentia

https://www.tcr.lu.se/research-groups/molecular-tumor-pathology - 2025-04-25

Brain Tumor Biology

PI Alexander Pietras BackgroundGlioblastoma multiforme (GBM) the highest-grade glioma and deadliest brain tumor occurs in pediatric as well as adult patients. Despite aggressive treatment with surgery, irradiation and sometimes chemotherapy, tumors invariably recur as incurable lesions. Tumor cells with stem cell characteristics are thought to be responsible for therapeutic resistance in brain tum

https://www.tcr.lu.se/research-groups/brain-tumor-biology - 2025-04-25

Experimental Oncology

PI Kristian Pietras Our researchOur aim is to molecularly map support functions performed by the various cell types comprising the tumor microenvironment. We believe that decisive treatment benefit can only be achieved by targeting several of the cell types that collectively sustain tumor growth. Importantly, the cellular networks within tumors cannot be studied in isolation. Thus, our work ranges

https://www.tcr.lu.se/research-groups/experimental-oncology - 2025-04-25

Molecular Cancer Research

PI Lars Rönnstrand BackgroundThe receptor tyrosine kinases KIT and FLT3 are both important regulators of development and maintenance of a number of different cell types. Deregulation of these receptors by mutations has been implicated in various human malignancies, including akut myeloid leukemia and melanoma. The signaling pathways activated by the oncogenic mutants are to some extent unique and

https://www.tcr.lu.se/research-groups/molecular-cancer-research - 2025-04-25

Molecular Cancer Medicine

PI Kazi Julhash Uddin BackgroundDespite incredible progress in the treatment of cancer, the cure rate remains low due to the fact that almost all cancer patients develop resistance to anticancer therapies.  This results in as many as 90% of cancer-related deaths in various types of cancer. Consequently, identification of the factors that drive the development of therapy resistance is a pressing is

https://www.tcr.lu.se/research-groups/molecular-cancer-medicine - 2025-04-25